Welcome to our dedicated page for Neogen SEC filings (Ticker: NEOG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Food safety diagnostics might feel far from Wall Street, yet Neogen’s supply-chain complexity shows up in hundreds of pages of disclosures. Tracking which genomic test kit drives revenue, or when management sells shares, is difficult. That’s why investors hunting for “Neogen insider trading Form 4 transactions” or the latest “Neogen quarterly earnings report 10-Q filing” often lose hours scrolling through EDGAR.
Stock Titan fixes this. Our AI reads every 10-K, 10-Q, 8-K and proxy the moment it is released, pushes “Neogen Form 4 insider transactions real-time” to your dashboard, and offers “Neogen SEC filings explained simply” with crisp language and data visualizations. Within seconds you’ll see a “Neogen earnings report filing analysis,” flagging segment sales for food safety, animal safety and genomics, plus cash flow shifts tied to acquisitions. Interactive links jump you straight to risk factors, while sidebars answer “understanding Neogen SEC documents with AI” without legalese.
Want specifics? The “Neogen annual report 10-K simplified” highlights R&D spend on LAMP molecular assays and global compliance costs. The “Neogen proxy statement executive compensation” module benchmarks pay packages against peer diagnostics firms. Alerts on “Neogen executive stock transactions Form 4” reveal buying patterns before material announcements, and our dashboard keeps the “Neogen 8-K material events explained” in plain sight when recalls or mergers hit. Whether you compare quarter-over-quarter allergen test kit sales, monitor insider sentiment, or review governance votes, Stock Titan delivers the intelligence you need, updated in real time and ready for decision making.
NEOGEN CORP (NEOG) director Rafael A. Rodriguez received 2,071 restricted stock units that vested and were settled into 2,071 shares of common stock on
Ashima Gupta, a director of Neogen Corporation (NEOG), reported the vesting and settlement of 2,071 restricted stock units (RSUs) into 2,071 shares of common stock on
The filing is a routine Section 16 disclosure showing compensation‑related equity vesting rather than an open‑market buy or sell. The form was signed by an attorney‑in‑fact on
Neogen Corp director Ronald D. Green had 2,071 restricted stock units (RSUs) vest on
Jeffrey D. Capello, a director of Neogen Corporation (NEOG), had 2,071 restricted stock units vest and settle on
The settlement converted the RSUs into 2,071 shares of common stock at an indicated unit price of
Insider report: A director of Neogen Corporation (NEOG) had 2,071 restricted stock units vest and be settled for 2,071 shares of common stock on
William T. Boehm, a director of Neogen Corp (NEOG), had 2,071 restricted stock units vest and be settled into 2,071 shares of Common Stock on
Neogen Corp (NEOG) reported transactional and control updates for the quarter ended
The filing describes how certain executive Performance Stock Units (PSUs) will be settled after the end of the Performance Period. An independent committee will compare the Companys actual performance to the pre-established metrics and apply an rTSR multiplier to determine how many PSUs, if any, are earned. Any earned PSUs will be converted into shares of the Companys common stock and issued to the named executive officer as soon as practicable, and those shares will be fully vested upon issuance. Until settlement, the PSUs do not give the executives any ownership interest or shareholder rights.